Investigational New Drugs · 2013 · 23 citations · 28 references
MedicineCancer BiologyOncologyCell SignalingMolecular OncologyNeoplasiaCancer Cell SignalingMetastatic Signaling PathwaysOncogene AddictionSignal Transduction In CancerTherapeutic ResistanceAnticancer Drug ResistanceCancer Signaling PathwaysMet InhibitorsMet Receptor Tyrosine KinaseMet-targeted TherapyProtein Kinase InhibitorsTherapeutic Resistance Mechanisms
28
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Jiřina Bártková, Zuzana Hořejšı́, Karen Koed et al. · Nature · 2005 · 2.7K citations
Medicine, Cancer Biology, Oncology +16